Aratana Therapeutics Stock Price, News & Analysis (NASDAQ:PETX)

$5.73 0.15 (2.69 %)
(As of 12/17/2017 12:35 PM ET)
Previous Close$5.73
Today's Range$5.56 - $5.82
52-Week Range$4.97 - $8.63
Volume504,821 shs
Average Volume588,738 shs
Market Capitalization$246.39 million
P/E RatioN/A
Dividend YieldN/A
Beta3.36

About Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics logoAratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.

Receive PETX News and Ratings via Email

Sign-up to receive the latest news and ratings for PETX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Veterinary Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:PETX
CUSIPN/A
Phone+1-913-3531000

Debt

Debt-to-Equity Ratio0.26%
Current Ratio3.42%
Quick Ratio3.08%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$38.55 million
Price / Sales6.39
Cash FlowN/A
Price / CashN/A
Book Value$2.44 per share
Price / Book2.35

Profitability

Trailing EPS($1.45)
Net Income$-33,570,000.00
Net Margins-358.55%
Return on Equity-48.79%
Return on Assets-30.52%

Miscellaneous

Employees85
Outstanding Shares43,000,000

Aratana Therapeutics (NASDAQ:PETX) Frequently Asked Questions

What is Aratana Therapeutics' stock symbol?

Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."

How were Aratana Therapeutics' earnings last quarter?

Aratana Therapeutics, Inc. (NASDAQ:PETX) issued its quarterly earnings data on Thursday, November, 2nd. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.24) by $0.03. The biopharmaceutical company had revenue of $6.16 million for the quarter, compared to the consensus estimate of $6.47 million. Aratana Therapeutics had a negative return on equity of 48.79% and a negative net margin of 358.55%. The firm's revenue was up 1440.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.38) EPS. View Aratana Therapeutics' Earnings History.

When will Aratana Therapeutics make its next earnings announcement?

Aratana Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 12th 2018. View Earnings Estimates for Aratana Therapeutics.

Where is Aratana Therapeutics' stock going? Where will Aratana Therapeutics' stock price be in 2017?

5 brokerages have issued 1 year price objectives for Aratana Therapeutics' shares. Their forecasts range from $7.00 to $10.00. On average, they expect Aratana Therapeutics' share price to reach $9.00 in the next year. View Analyst Ratings for Aratana Therapeutics.

What are Wall Street analysts saying about Aratana Therapeutics stock?

Here are some recent quotes from research analysts about Aratana Therapeutics stock:

  • 1. According to Zacks Investment Research, "Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. " (11/18/2017)
  • 2. Jefferies Group LLC analysts commented, "Q4'16 results uneventful. The Nocita and Galliprant launches are progressing and Entyce is on track for late '17 launch. However, we think the sell-off on the Q4 results was primarily driven by concerns around the cash runway and how this will be addressed. We like the risk/ reward at this level and reiterate our Buy rating. PT lowered to $8 (from $11)." (3/16/2017)
  • 3. Stifel Nicolaus analysts commented, "Friday evening, Aratana announced that the launch of ENTYCE (capromorelin oral solution to treat inappetence for dogs) will be pushed out to late 2017 versus prior expectations of 1Q17. While the modest delay does not materially alter our peak sales expectations, it is the latest in a series of setbacks that have weighed on the company. In September 2015, Aratana's canine lymphoma initiative hit a meaningful roadblock, causing us to significantly curtail future sales expectations. More recently, a couple of other indications have taken longer to get to market due to resets with pilot studies (feline and AT-018), been de-prioritized (AT-007 feline immunodeficiency virus), or eliminated altogether (AT-011 canine parvovirus). The latest setback with ENTYCE is related to production/commercialization, and when combined with prior speed bumps, pushes the company's commercial sales traction out to 2018 (ENTYCE previously accounted for 75% of our 2017E sales). In our opinion, Aratana's story has subtly changed from that of revenue diversification (handful of drugs each accounting for 10-20% of sales) to one that is concentrated, with two drugs accounting for the majority of future sales. With this in mind, and the latest commercial setback which has now caused us to take a more conservative stance around the timeline for other indications, we downgrade to Hold (lower TP from $11 to $8) and wait for better visibility in the coming quarters (canine NOCITA and ENTYCE sales ramp, feline clinical initiatives)." (2/6/2017)

Who are some of Aratana Therapeutics' key competitors?

Who are Aratana Therapeutics' key executives?

Aratana Therapeutics' management team includes the folowing people:

  • Wendy L. Yarno, Chairman of the Board (Age 63)
  • Steven St. Peter M.D., President, Chief Executive Officer, Director (Age 49)
  • Craig A. Tooman, Chief Financial Officer, Treasurer (Age 49)
  • Brent Standridge, Chief Operating Officer (Age 58)
  • Ernst Heinen Ph.D., Chief Development Officer (Age 52)
  • Laura A. Brege, Independent Director (Age 59)
  • David L. Brinkley, Independent Director (Age 57)
  • Robert Benthall Gerber Jr., Independent Director (Age 52)
  • Irvine O. Hockaday Jr. Esq., Independent Director (Age 81)
  • Merilee Raines, Independent Director (Age 61)

Who owns Aratana Therapeutics stock?

Aratana Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (4.19%), Alyeska Investment Group L.P. (2.24%), General American Investors Co. Inc. (2.02%), Dimensional Fund Advisors LP (0.90%), Wells Fargo & Company MN (0.85%) and Cadence Capital Management LLC (0.40%). Company insiders that own Aratana Therapeutics stock include Brent Standridge, Craig A Tooman, Ernst Heinen, Healthcare Master Fun Broadfin, Julia A Stephanus and Peter Steven St. View Institutional Ownership Trends for Aratana Therapeutics.

Who sold Aratana Therapeutics stock? Who is selling Aratana Therapeutics stock?

Aratana Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Sheaff Brock Investment Advisors LLC and California State Teachers Retirement System. Company insiders that have sold Aratana Therapeutics company stock in the last year include Brent Standridge, Ernst Heinen, Healthcare Master Fun Broadfin and Peter Steven St. View Insider Buying and Selling for Aratana Therapeutics.

Who bought Aratana Therapeutics stock? Who is buying Aratana Therapeutics stock?

Aratana Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including General American Investors Co. Inc., Alyeska Investment Group L.P., Wells Fargo & Company MN, Janus Henderson Group PLC, Cadence Capital Management LLC and Dimensional Fund Advisors LP. View Insider Buying and Selling for Aratana Therapeutics.

How do I buy Aratana Therapeutics stock?

Shares of Aratana Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aratana Therapeutics' stock price today?

One share of Aratana Therapeutics stock can currently be purchased for approximately $5.73.

How big of a company is Aratana Therapeutics?

Aratana Therapeutics has a market capitalization of $246.39 million and generates $38.55 million in revenue each year. The biopharmaceutical company earns $-33,570,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Aratana Therapeutics employs 85 workers across the globe.

How can I contact Aratana Therapeutics?

Aratana Therapeutics' mailing address is 11400 Tomahawk Creek Pkwy Ste 340, LEAWOOD, KS 66211-2730, United States. The biopharmaceutical company can be reached via phone at +1-913-3531000 or via email at [email protected]


MarketBeat Community Rating for Aratana Therapeutics (PETX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  231 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  369
MarketBeat's community ratings are surveys of what our community members think about Aratana Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aratana Therapeutics (NASDAQ:PETX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.002.86
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.67$9.67$9.40$9.83
Price Target Upside: 39.29% upside39.29% upside75.05% upside58.60% upside

Aratana Therapeutics (NASDAQ:PETX) Consensus Price Target History

Price Target History for Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics (NASDAQ:PETX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/17/2017HC WainwrightInitiated CoverageBuy -> Buy$10.00N/AView Rating Details
11/16/2017Jefferies GroupSet Price TargetBuy$9.00N/AView Rating Details
8/25/2017Lake Street CapitalLower Price TargetBuy -> Buy$15.00 -> $10.00LowView Rating Details
5/10/2017Stifel NicolausLower Price TargetBuy -> Buy$8.00 -> $7.00LowView Rating Details
2/9/2017William BlairReiterated RatingOutperformN/AView Rating Details
8/11/2016BarclaysLower Price TargetOverweight$15.00 -> $11.00N/AView Rating Details
8/10/2016Credit Suisse GroupReiterated RatingBuy$11.00N/AView Rating Details
3/16/2016Craig HallumLower Price TargetHold$11.00 -> $7.00N/AView Rating Details
(Data available from 12/17/2015 forward)

Earnings

Aratana Therapeutics (NASDAQ:PETX) Earnings History and Estimates Chart

Earnings by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics (NASDAQ PETX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018($0.23)N/AView Earnings Details
11/2/2017Q3 2017($0.24)($0.21)$6.47 million$6.16 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.29)($0.26)$4.50 million$5.16 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.34)($0.34)$3.05 million$3.80 millionViewListenView Earnings Details
3/13/2017Q4 2016($0.42)($0.64)$0.80 million$0.29 millionViewN/AView Earnings Details
11/3/2016Q316($0.48)($0.38)$0.13 million$0.04 millionViewN/AView Earnings Details
8/4/2016Q216$0.24$0.61$15.14 million$38.05 millionViewN/AView Earnings Details
5/5/2016Q116($0.42)($0.52)$0.13 million$0.17 millionViewN/AView Earnings Details
3/14/2016Q415($0.41)($0.37)$0.21 million$0.06 millionViewN/AView Earnings Details
11/5/2015Q315($0.39)($1.58)$0.21 million$0.23 millionViewN/AView Earnings Details
8/6/2015Q2($0.38)($0.23)$0.18 million$0.23 millionViewN/AView Earnings Details
5/7/2015($0.40)($0.26)$0.30 million$0.16 millionViewN/AView Earnings Details
3/12/2015Q315($0.35)($0.30)$0.10 million$0.25 millionViewN/AView Earnings Details
11/10/2014Q315($0.41)($0.35)$0.25 million$0.43 millionViewN/AView Earnings Details
8/12/2014Q215($0.36)($0.32)$0.14 million$0.30 millionViewN/AView Earnings Details
5/13/2014Q115($0.35)($0.34)$0.09 million$0.18 millionViewN/AView Earnings Details
3/13/2014Q414($0.21)$0.40ViewN/AView Earnings Details
11/13/2013Q3($0.20)($0.22)ViewN/AView Earnings Details
8/12/2013Q2($10.21)($4.62)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Aratana Therapeutics (NASDAQ:PETX) Earnings Estimates

2017 EPS Consensus Estimate: ($1.10)
2018 EPS Consensus Estimate: ($0.32)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.35)($0.29)($0.31)
Q2 20173($0.33)($0.28)($0.30)
Q3 20173($0.30)($0.24)($0.26)
Q4 20173($0.27)($0.19)($0.23)
Q1 20182($0.18)($0.16)($0.17)
Q2 20182($0.15)($0.13)($0.14)
Q3 20182($0.14)($0.09)($0.12)
Q4 20182($0.04)$0.25$0.11
Q1 20192($0.10)$0.03($0.04)
Q2 20192$0.02$0.06$0.04
Q3 20191$0.10$0.10$0.10
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aratana Therapeutics (NASDAQ:PETX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Aratana Therapeutics (NASDAQ PETX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.20%
Institutional Ownership Percentage: 73.95%
Insider Trades by Quarter for Aratana Therapeutics (NASDAQ:PETX)
Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Aratana Therapeutics (NASDAQ PETX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/1/2017Healthcare Master Fun BroadfinMajor ShareholderSell890,516$5.70$5,075,941.20View SEC Filing  
11/29/2017Healthcare Master Fun BroadfinMajor ShareholderSell116,516$6.53$760,849.48View SEC Filing  
11/10/2017Peter Steven StInsiderSell50,000$7.00$350,000.00View SEC Filing  
10/2/2017Peter Steven StInsiderSell50,000$6.24$312,000.00View SEC Filing  
9/25/2017Brent StandridgeCOOSell10,000$6.11$61,100.00View SEC Filing  
9/15/2017Ernst HeinenInsiderSell10,000$6.25$62,500.00View SEC Filing  
4/17/2017Peter Steven StInsiderSell50,000$5.54$277,000.00View SEC Filing  
1/27/2017Peter Steven StInsiderSell50,000$7.72$386,000.00View SEC Filing  
12/15/2016Peter Steven StInsiderSell50,000$7.63$381,500.00View SEC Filing  
10/3/2016Ernst HeinenInsiderSell10,000$10.00$100,000.00View SEC Filing  
9/9/2016Craig A ToomanInsiderSell30,000$9.25$277,500.00View SEC Filing  
8/9/2016Peter Steven StInsiderSell50,000$9.25$462,500.00View SEC Filing  
6/28/2016Julia A StephanusInsiderSell30,000$6.25$187,500.00View SEC Filing  
6/17/2016Peter Steven StCEOSell100,000$6.26$626,000.00View SEC Filing  
6/10/2016Ernst HeinenInsiderSell15,000$6.72$100,800.00View SEC Filing  
2/1/2016Craig A ToomanCFOSell2,806$3.36$9,428.16View SEC Filing  
11/9/2015Craig A ToomanCFOSell3,620$7.52$27,222.40View SEC Filing  
10/2/2015Craig A ToomanCFOSell3,250$8.06$26,195.00View SEC Filing  
7/15/2015Ernst HeinenInsiderSell15,000$17.06$255,900.00View SEC Filing  
4/27/2015Linda RhodesInsiderSell15,000$15.00$225,000.00View SEC Filing  
3/6/2015Linda RhodesInsiderSell20,000$20.00$400,000.00View SEC Filing  
3/6/2015Vort John VanderDirectorSell6,137$20.01$122,801.37View SEC Filing  
1/13/2015Julia A StephanusInsiderSell6,300$19.00$119,700.00View SEC Filing  
1/13/2015Peter Steven StCEOSell75,000$19.23$1,442,250.00View SEC Filing  
12/22/2014Linda RhodesInsiderSell10,000$18.00$180,000.00View SEC Filing  
7/3/2014Julia A StephanusInsiderSell2,000$17.33$34,660.00View SEC Filing  
7/1/2014Linda RhodesInsiderSell10,000$16.00$160,000.00View SEC Filing  
6/17/2014Linda RhodesInsiderSell4,626$15.00$69,390.00View SEC Filing  
6/16/2014Julia A StephanusInsiderSell8,000$13.90$111,200.00View SEC Filing  
6/2/2014Peter Steven StCEOSell25,000$13.47$336,750.00View SEC Filing  
5/5/2014Ernst HeinenInsiderSell10,000$13.42$134,200.00View SEC Filing  
2/3/2014Ronald MeeusenDirectorSell500,000$19.00$9,500,000.00View SEC Filing  
7/2/2013Julia A StephanusInsiderBuy2,000$6.00$12,000.00View SEC Filing  
7/2/2013Peter Steven StCEOBuy8,333$6.00$49,998.00View SEC Filing  
7/2/2013Ventures Ix L.P. AvalonMajor ShareholderBuy500,000$6.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aratana Therapeutics (NASDAQ PETX) News Headlines

Source:
DateHeadline
Aratana Therapeutics (PETX) Reports Study Results for AT-016 - StreetInsider.comAratana Therapeutics (PETX) Reports Study Results for AT-016 - StreetInsider.com
www.streetinsider.com - December 17 at 10:13 AM
Aratana Therapeutics Announces Study Results for AT-016Aratana Therapeutics Announces Study Results for AT-016
finance.yahoo.com - December 15 at 4:54 PM
Aratana Therapeutics, Inc. (PETX) Receives Average Recommendation of "Hold" from BrokeragesAratana Therapeutics, Inc. (PETX) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 11 at 4:30 PM
ETFs with exposure to Aratana Therapeutics, Inc. : December 8, 2017ETFs with exposure to Aratana Therapeutics, Inc. : December 8, 2017
finance.yahoo.com - December 8 at 4:35 PM
With its stock still sinking, what it means that Aratana pulled a $35M offeringWith its stock still sinking, what it means that Aratana pulled a $35M offering
www.bizjournals.com - December 7 at 4:55 PM
-$0.23 Earnings Per Share Expected for Aratana Therapeutics, Inc. (PETX) This Quarter-$0.23 Earnings Per Share Expected for Aratana Therapeutics, Inc. (PETX) This Quarter
www.americanbankingnews.com - December 6 at 11:18 AM
Aratana Therapeutics, Inc. (PETX) Major Shareholder Healthcare Master Fun Broadfin Sells 116,516 SharesAratana Therapeutics, Inc. (PETX) Major Shareholder Healthcare Master Fun Broadfin Sells 116,516 Shares
www.americanbankingnews.com - December 1 at 9:02 PM
Aratana Therapeutics, Inc. (PETX) Major Shareholder Healthcare Master Fun Broadfin Sells 890,516 SharesAratana Therapeutics, Inc. (PETX) Major Shareholder Healthcare Master Fun Broadfin Sells 890,516 Shares
www.americanbankingnews.com - December 1 at 8:38 PM
Aratana cancels stock offering after shares plunge - MarketWatchAratana cancels stock offering after shares plunge - MarketWatch
www.marketwatch.com - November 30 at 10:55 AM
Why Aratana Therapeutics Inc. Is Tanking Today - Motley FoolWhy Aratana Therapeutics Inc. Is Tanking Today - Motley Fool
www.fool.com - November 30 at 10:55 AM
Aratana Therapeutics, Inc. Announces Termination of Offering of Common StockAratana Therapeutics, Inc. Announces Termination of Offering of Common Stock
finance.yahoo.com - November 29 at 10:22 AM
Aratana cancels stock offering after shares plungeAratana cancels stock offering after shares plunge
finance.yahoo.com - November 29 at 10:22 AM
Why Momo, Aratana Therapeutics, and Sea Limited Slumped TodayWhy Momo, Aratana Therapeutics, and Sea Limited Slumped Today
finance.yahoo.com - November 28 at 4:35 PM
Aratana Therapeutics (PETX) Commences $35M Common Stock OfferingAratana Therapeutics (PETX) Commences $35M Common Stock Offering
www.streetinsider.com - November 28 at 10:34 AM
Aratana Therapeutics, Inc. Announces Proposed Public OfferingAratana Therapeutics, Inc. Announces Proposed Public Offering
finance.yahoo.com - November 27 at 4:36 PM
ETFs with exposure to Aratana Therapeutics, Inc. : November 24, 2017ETFs with exposure to Aratana Therapeutics, Inc. : November 24, 2017
finance.yahoo.com - November 24 at 5:42 PM
Aratana Therapeutics, Inc. (PETX) Expected to Post Quarterly Sales of $7.25 MillionAratana Therapeutics, Inc. (PETX) Expected to Post Quarterly Sales of $7.25 Million
www.americanbankingnews.com - November 20 at 6:50 AM
Zacks: Brokerages Expect Aratana Therapeutics, Inc. (PETX) Will Post Earnings of -$0.23 Per ShareZacks: Brokerages Expect Aratana Therapeutics, Inc. (PETX) Will Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - November 18 at 1:26 PM
Aratana Therapeutics, Inc. (PETX) Given a $9.00 Price Target at Jefferies Group LLCAratana Therapeutics, Inc. (PETX) Given a $9.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - November 18 at 12:52 PM
Aratana Therapeutics, Inc. (PETX) Coverage Initiated by Analysts at HC WainwrightAratana Therapeutics, Inc. (PETX) Coverage Initiated by Analysts at HC Wainwright
www.americanbankingnews.com - November 18 at 11:38 AM
Aratana Therapeutics, Inc. (PETX) Downgraded by Zacks Investment Research to "Hold"Aratana Therapeutics, Inc. (PETX) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - November 18 at 6:04 AM
Aratana Therapeutics, Inc. (PETX) to Post FY2017 Earnings of ($1.04) Per Share, Jefferies Group ForecastsAratana Therapeutics, Inc. (PETX) to Post FY2017 Earnings of ($1.04) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - November 17 at 8:30 PM
Aratana Therapeutics, Inc. (PETX) Receives Average Rating of "Hold" from BrokeragesAratana Therapeutics, Inc. (PETX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 16 at 2:02 PM
ETFs with exposure to Aratana Therapeutics, Inc. : November 13, 2017ETFs with exposure to Aratana Therapeutics, Inc. : November 13, 2017
finance.yahoo.com - November 14 at 6:42 AM
Peter Steven St Sells 50,000 Shares of Aratana Therapeutics, Inc. (PETX) StockPeter Steven St Sells 50,000 Shares of Aratana Therapeutics, Inc. (PETX) Stock
www.americanbankingnews.com - November 13 at 7:26 PM
Aratana Therapeutics (PETX) and Eli Lily (LLY) Division Elanco Animal Health Reports Positive Opinion on ... - StreetInsider.comAratana Therapeutics (PETX) and Eli Lily (LLY) Division Elanco Animal Health Reports Positive Opinion on ... - StreetInsider.com
www.streetinsider.com - November 12 at 11:35 AM
With three products out, Aratana chases its fourth: a canine cancer drugWith three products out, Aratana chases its fourth: a canine cancer drug
finance.yahoo.com - November 9 at 11:16 AM
FY2017 Earnings Estimate for Aratana Therapeutics, Inc. Issued By William Blair (PETX)FY2017 Earnings Estimate for Aratana Therapeutics, Inc. Issued By William Blair (PETX)
www.americanbankingnews.com - November 9 at 7:21 AM
William Blair Comments on Aratana Therapeutics, Inc.s FY2020 Earnings (PETX)William Blair Comments on Aratana Therapeutics, Inc.'s FY2020 Earnings (PETX)
www.americanbankingnews.com - November 8 at 10:44 PM
Aratana Therapeutics, Inc. :PETX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017Aratana Therapeutics, Inc. :PETX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 7 at 8:37 AM
Aratana Therapeutics, Inc. (PETX) Rating Reiterated by Jefferies Group LLCAratana Therapeutics, Inc. (PETX) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - November 5 at 5:40 PM
Your Daily Pharma Scoop: Timing Synergy Trade, Valeants Vyzulta Approved, Seattle Genetics Files SBLA For Adcetris - Seeking AlphaYour Daily Pharma Scoop: Timing Synergy Trade, Valeant's Vyzulta Approved, Seattle Genetics Files SBLA For Adcetris - Seeking Alpha
seekingalpha.com - November 4 at 8:51 AM
Your Daily Pharma Scoop: Timing Synergy Trade, Valeants Vyzulta Approved, Seattle Genetics Files SBLA For Adcetris - Seeking AlphaYour Daily Pharma Scoop: Timing Synergy Trade, Valeant's Vyzulta Approved, Seattle Genetics Files SBLA For Adcetris - Seeking Alpha
seekingalpha.com - November 4 at 8:51 AM
What Does Aratana Therapeutics Inc’s (PETX) Share Price Indicate?What Does Aratana Therapeutics Inc’s (PETX) Share Price Indicate?
finance.yahoo.com - November 4 at 8:50 AM
What Does Aratana Therapeutics Inc’s (PETX) Share Price Indicate?What Does Aratana Therapeutics Inc’s (PETX) Share Price Indicate?
finance.yahoo.com - November 4 at 8:50 AM
Aratana Therapeutics Reports Third Quarter 2017 Financial ResultsAratana Therapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 4 at 8:50 AM
Aratana Therapeutics Reports Third Quarter 2017 Financial ResultsAratana Therapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 4 at 8:50 AM
Aratana reports 3Q lossAratana reports 3Q loss
finance.yahoo.com - November 4 at 8:50 AM
Aratana reports 3Q lossAratana reports 3Q loss
finance.yahoo.com - November 4 at 8:50 AM
Aratana Therapeutics, Inc. to Host Earnings CallAratana Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - November 4 at 8:50 AM
Aratana Therapeutics, Inc. to Host Earnings CallAratana Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - November 4 at 8:50 AM
ETFs with exposure to Aratana Therapeutics, Inc. : November 3, 2017ETFs with exposure to Aratana Therapeutics, Inc. : November 3, 2017
finance.yahoo.com - November 4 at 8:50 AM
ETFs with exposure to Aratana Therapeutics, Inc. : November 3, 2017ETFs with exposure to Aratana Therapeutics, Inc. : November 3, 2017
finance.yahoo.com - November 4 at 8:50 AM
Edited Transcript of PETX earnings conference call or presentation 3-Nov-17 12:30pm GMTEdited Transcript of PETX earnings conference call or presentation 3-Nov-17 12:30pm GMT
finance.yahoo.com - November 4 at 8:50 AM
Edited Transcript of PETX earnings conference call or presentation 3-Nov-17 12:30pm GMTEdited Transcript of PETX earnings conference call or presentation 3-Nov-17 12:30pm GMT
finance.yahoo.com - November 4 at 8:50 AM
Aratana Therapeutics, Inc. (PETX) Posts  Earnings Results, Beats Estimates By $0.03 EPSAratana Therapeutics, Inc. (PETX) Posts Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - November 3 at 6:24 PM
Aratana Therapeutics to Present at Credit Suisse Healthcare Conference - PR Newswire (press release)Aratana Therapeutics to Present at Credit Suisse Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - November 1 at 7:29 AM
Aratana Therapeutics to Present at Credit Suisse Healthcare ConferenceAratana Therapeutics to Present at Credit Suisse Healthcare Conference
finance.yahoo.com - October 31 at 7:48 AM
Aratana Therapeutics, Inc. (PETX) to Release Quarterly Earnings on WednesdayAratana Therapeutics, Inc. (PETX) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 25 at 6:30 AM
Aratana Therapeutics, Inc. (PETX) Receives Consensus Recommendation of "Hold" from AnalystsAratana Therapeutics, Inc. (PETX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 22 at 2:26 PM

SEC Filings

Aratana Therapeutics (NASDAQ:PETX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aratana Therapeutics (NASDAQ:PETX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aratana Therapeutics (NASDAQ PETX) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.